SWOG clinical trial number
SWOG-9221 (MDACC, ID91-025) (INT-I91-0001)
Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer
Closed
Phase
Published
Abbreviated Title
Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer
Activated
03/15/1993
Closed
04/09/1997
Research committees
Lung Cancer
Publication Information Expand/Collapse
2001
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.
1998
Phase III intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage-I non-small cell lung cancer (NSCLC): Interim report of NCI #191-0001.
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
85%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open